Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit
Authors
Keywords
Sorafenib, Sunitinib, Vascular Endothelial Growth Factor Receptor, Pazopanib, Axitinib
Journal
DRUG SAFETY
Volume 38, Issue 8, Pages 693-710
Publisher
Springer Nature
Online
2015-05-25
DOI
10.1007/s40264-015-0300-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Detailed Description and Assessment of Outcomes of Patients With Hospital Recorded QTc Prolongation
- (2015) Zachary Laksman et al. AMERICAN JOURNAL OF CARDIOLOGY
- Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902
- (2015) S. Sugawara et al. ANNALS OF ONCOLOGY
- Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
- (2015) J S L Kloth et al. BRITISH JOURNAL OF CANCER
- FGF2 Prevents Sunitinib-Induced Cardiotoxicity in Zebrafish and Cardiomyoblast H9c2 Cells
- (2015) Guozhen Cui et al. Cardiovascular Toxicology
- Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
- (2015) Pooja Ghatalia et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Fatal adverse drug reactions of anticancer drugs detected by all-case post-marketing surveillance in Japan
- (2015) J. Mori et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
- (2015) Masayuki Takeda et al. LUNG CANCER
- Primary gastrointestinal stromal tumor of the liver treated with sequential therapy
- (2015) Xian-Ke Lin WORLD JOURNAL OF GASTROENTEROLOGY
- Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study
- (2015) Amirrtha Srikanthan et al. PLoS One
- QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
- (2014) P Ghatalia et al. BRITISH JOURNAL OF CANCER
- Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials
- (2014) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
- (2014) Ole-Petter R. Hamnvik et al. CANCER
- Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms
- (2014) Sariah Liu et al. CANCER TREATMENT REVIEWS
- Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trials
- (2014) Tomohiro Funakoshi et al. CANCER TREATMENT REVIEWS
- Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis
- (2014) Wei-Xiang Qi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: An updated systematic review and comparative meta-analysis
- (2014) Omar Abdel-Rahman et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Evaluation of second line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first line cediranib
- (2014) Suzanne Richter et al. CUAJ-Canadian Urological Association Journal
- Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices
- (2014) Eric Jonasch et al. CURRENT MEDICAL RESEARCH AND OPINION
- Cancer Therapy-Induced Left Ventricular Dysfunction: Interventions and Prognosis
- (2014) Akanksha Thakur et al. JOURNAL OF CARDIAC FAILURE
- An update on cardio-oncology
- (2014) Joerg Herrmann et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials
- (2014) Shaodong Hong et al. OncoTargets and Therapy
- Adverse reactions to oncologic drugs: spontaneous reporting and signal detection
- (2014) Marco Tuccori et al. Expert Review of Clinical Pharmacology
- A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors
- (2013) Rashmi R. Shah et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis
- (2013) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Developing Standards for Breakthrough Therapy Designation in Oncology
- (2013) S. J. Horning et al. CLINICAL CANCER RESEARCH
- Clinical Pharmacology and the Catalysis of Regulatory Science: Opportunities for the Advancement of Drug Development and Evaluation
- (2013) I Zineh et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Integrating Clinical Pharmacology Concepts in Individualized Therapy With Tyrosine Kinase Inhibitors
- (2013) C D Drenberg et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
- (2013) Elisabetta Poluzzi et al. DRUG SAFETY
- Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
- (2013) Devron R. Shah et al. DRUG SAFETY
- Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)
- (2013) Rashmi R. Shah et al. DRUG SAFETY
- Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics
- (2013) Pieter G. Postema et al. EUROPACE
- Evaluation of FDA safety-related drug label changes in 2010
- (2013) Jean Lester et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
- (2013) Hong-bing Liu et al. PLoS One
- Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: A meta-analysis of 22 phase III randomized controlled trials
- (2013) Wei-Xiang Qi et al. RESPIRATORY MEDICINE
- Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors
- (2012) Richard M. Steingart et al. AMERICAN HEART JOURNAL
- Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials
- (2012) F. Petrelli et al. ANNALS OF ONCOLOGY
- Blocking of the Human Ether-^|^agrave;-go-go-Related Gene Channel by Imatinib Mesylate
- (2012) Qian Dong et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials
- (2012) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis
- (2012) Wei-Xiang Qi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis
- (2012) Shanthi Sivendran et al. CANCER TREATMENT REVIEWS
- Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials
- (2012) Yong-Ying Xiao et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Successful Treatment of Non-small Cell Lung Cancer with Gefitinib after Severe Erlotinib-related Hepatotoxicity
- (2012) Kei Kunimasa et al. INTERNAL MEDICINE
- The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
- (2012) Saroj Niraula et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
- (2012) Fabio A.B. Schutz et al. JOURNAL OF CLINICAL ONCOLOGY
- Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France?
- (2012) Marie-Noelle Paludetto et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs
- (2011) Eitan Amir et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib
- (2011) Christopher J. Richards et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
- (2010) Thomas Eschenhagen et al. EUROPEAN JOURNAL OF HEART FAILURE
- The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients
- (2010) Milena S. Marcolino et al. HEMATOLOGICAL ONCOLOGY
- Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
- (2010) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials
- (2010) Bostjan Seruga et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies
- (2010) Armin Wolf et al. LEUKEMIA RESEARCH
- A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib
- (2010) Zahra Raisi Estabragh et al. LEUKEMIA RESEARCH
- Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity
- (2010) Geoffrey Y. Ku et al. LUNG CANCER
- The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro
- (2010) Brian B. Hasinoff et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Evaluation and Management of Cardiac Safety Using the Electrocardiogram in Oncology Clinical Trials: Focus on Cardiac Repolarization (QTc Interval)
- (2009) J Morganroth et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Gastrointestinal toxicities of novel agents in cancer therapy
- (2009) Amani Asnacios et al. EUROPEAN JOURNAL OF CANCER
- Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions
- (2009) Hester van Cruijsen Frontiers in Bioscience-Landmark
- Quantitative signal detection using spontaneous ADR reporting
- (2009) A. Bate et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started